ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead
Increased Expenses Fail To Knock The Wind From ANI’s Wings
Executive Summary
ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.
You may also be interested in...
ANI Revises Its Expectations Up Following Record Revenues
ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.
ANI Plans To Shutter Oakville Plant By Q1 2023
ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.
ANI Delivers On Cortrophin Gel US Launch
ANI Pharmaceuticals has finally delivered its long-awaited launch of purified Cortrophin Gel (repository corticotropin injection) in the US, accompanying the launch with its ‘Cortrophin In Your Corner’ dedicated program to increase access and provide reimbursement support.